All In Biotech

Drug Trial Radar · NCT06694701

Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Mar 14, 2025

Primary completion

Mar 13, 2026

Study completion Sep 14, 2026

Sponsor

Lead sponsor
Hellenic Institute for the Study of SepsisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.

Conditions

  • Sepsis

Interventions

  • Emapalumab-IzsgDrug

    The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.

  • Emapalumab-IzsgDrug

    The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.

  • PlaceboDrug

    250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Decrease of SOFA score by the end-of-treatmentTime frame: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Intensive Care Unit, Alexandroupolis University General Hospital

    Alexandroupoli, Greece

  • 3rd University Department of Internal Medicine, Sotiria Chest Diseases Athens General Hospital

    Athens, Greece

  • 4th Department of Internal Medicine, ATTIKON University General Hospital

    Athens, Greece

  • Intensive Care Unit I, KAT Attica General Hospital

    Athens, Greece

  • Intensive Care Unit of 1st University Department Respiratory Medicine, Sotiria Chest Diseases Athens General Hospital

    Athens, Greece

  • Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital

    Athens, Greece

  • Intensive Care Unit, Asklipieio Voulas General Hospital

    Athens, Greece

  • Intensive Care Unit, Ippokrateio Athens General Hospital

    Athens, Greece

  • Intensive Care Unit, Korgialeneio-Benakeio HRC Athens General Hospital

    Athens, Greece

  • Intensive Care Unit, Laiko Athens General Hospital

    Athens, Greece

  • New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital

    Athens, Greece

  • Ηigh Dependency Unit of Department of Clinical Therapeutics, Alexandra Athens General Hospital

    Athens, Greece

  • Intensive Care Unit, Patras University General Hospital

    Pátrai, Greece

  • 1st Intensive Care Unit, G. Papanikolaou Thessaloniki General Hospital

    Thessaloniki, Greece

  • Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital

    Thessaloniki, Greece

  • Intensive Care Unit, 424 General Military Training Hospital

    Thessaloniki, Greece

  • Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital

    Thessaloniki, Greece

  • Intensive Care Unit, G. Gennimatas Thessaloniki General Hospital

    Thessaloniki, Greece

  • Intensive Care Unit, Ippokrateio Thessaloniki General Hospital

    Thessaloniki, Greece

  • Intensive Care Unit, Papageorgiou Thessaloniki General Hospital

    Thessaloniki, Greece

  • Intensive Care Unit, Theageneio Thessaloniki Cancer Hospital

    Thessaloniki, Greece

  • 1st Department of Internal Medicine, Thriasio Elefsis General Hospital

    Elefsina, Attica, Greece

  • Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital

    Kifissia, Attica, Greece

  • Intensive Care Unit, University General Hospital of Heraklion

    Heraklion, Crete, Greece

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.